PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för suzetrigine. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

9 hits

Bibliografisk träff 2025-01-08

Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain.

Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, Aertgeerts K, Negulescu PA, Lechner SM.

Pain Ther · research-article; journal article · DOI 10.1007/s40122-024-00697-0

Bibliografisk träff 2024-11-19

Drugs in Development to Manage Acute Pain.

Oliver B, Devitt C, Park G, Razak A, Liu SM, Bergese SD.

Drugs · review; journal article · DOI 10.1007/s40265-024-02118-0

Bibliografisk träff 2024-11-18

State-Dependent Inhibition of Nav1.8 Sodium Channels by VX-150 and VX-548.

Vaelli P, Fujita A, Jo S, Zhang HB, Osorno T, Ma X, Bean BP.

Mol Pharmacol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/molpharm.124.000944

Bibliografisk träff 2024-10-17

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential.

Wang H, Huang J, Zang J, Jin X, Yan N.

Curr Opin Chem Biol · review; journal article · DOI 10.1016/j.cbpa.2024.102538

Bibliografisk träff 2024-09-01

VX-548 in the treatment of acute pain.

Hang Kong AY, Tan HS, Habib AS.

Pain Manag · review-article; review; journal article · DOI 10.1080/17581869.2024.2421749

Bibliografisk träff 2024-07-04

Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review.

Kaye AD, Everett ES, Lehuquet AM, Mason JW, Maitski R, Plessala MJ, Barrie S, Baptiste CJ, Mychaskiw G, Ahmadzadeh S, Shekoohi S, Varrassi G.

Curr Pain Headache Rep · review; journal article · DOI 10.1007/s11916-024-01295-7

Bibliografisk träff 2024-05-23

A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: Method validation and application to pharmacokinetic study.

Zhang H, Chen Y, Huang J, Sun W.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.5907

Bibliografisk träff 2024-04-04

Gender difference in the pharmacokinetics and metabolism of VX-548 in rats.

Yu G, Zhou X.

Biopharm Drug Dispos · journal article · DOI 10.1002/bdd.2387

Bibliografisk träff 2023-08-01

Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.

Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF, VX21-548-101 and VX21-548-102 Trial Groups.

N Engl J Med · randomized controlled trial; journal article · DOI 10.1056/nejmoa2209870

Go to research.

Publications in the selection

Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na<sub>V</sub>1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain.

Drugs in Development to Manage Acute Pain.

State-Dependent Inhibition of Nav1.8 Sodium Channels by VX-150 and VX-548.

Drug discovery targeting Na<sub>v</sub>1.8: Structural insights and therapeutic potential.

VX-548 in the treatment of acute pain.

Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review.

A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: Method validation and application to pharmacokinetic study.

Gender difference in the pharmacokinetics and metabolism of VX-548 in rats.

Selective Inhibition of Na<sub>V</sub>1.8 with VX-548 for Acute Pain.